TPCW
PTCT icon

TD Private Client Wealth’s PTC Therapeutics PTCT Stock Holding History

TD Private Client Wealth’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2K Buy
162
+14
+9% +$1.01K ﹤0.01% 1091
2026
Q1 		$10.1K Hold
148
– – ﹤0.01% 1099
2025
Q4 		$11.2K Sell
148
-204
-58% -$14.8K ﹤0.01% 1078
2025
Q3 		$21.6K Buy
+352
New +$18.3K ﹤0.01% 974

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

TD Private Client Wealth's PTCT Position: Q2 2026 in Review

TD Private Client Wealth increased its PTC Therapeutics (PTCT) stake by 9.5% in Q2 2026, buying an estimated $1.01K and bringing the position to 162 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

TD Private Client Wealth first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. The position peaked at $21.6K in Q3 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • TD Private Client Wealth held 162 shares of PTC Therapeutics worth $13.2K as of Q2 2026.
  • TD Private Client Wealth bought 14 PTC Therapeutics shares in Q2 2026, an estimated $1.01K.
  • PTC Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1091 holding.
  • TD Private Client Wealth first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • TD Private Client Wealth's PTC Therapeutics position peaked at $21.6K in Q3 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.